Real-World Comparison of Clopidogrel With Ticagrelor and Prasugrel in Patients With Chronic Coronary Disease Who Underwent Atherectomy.
作者信息
Khan Mahin R, Koshy Anoop N, Tanner Richard, Farhan Serdar, Vinayak Manish, Farooq Ali, Sartori Samantha, Feng Yihan, Spirito Alessandro, Arora Ayush, Dhulipala Vishal, Kapur Vishal, Suleman Javed, Sharma Raman, Mehran Roxana, Kini Annapoorna, Sharma Samin K
机构信息
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Am J Cardiol. 2024 Apr 15;217:1-4. doi: 10.1016/j.amjcard.2024.02.006. Epub 2024 Feb 23.
Abstract
摘要
相似文献
1
Real-World Comparison of Clopidogrel With Ticagrelor and Prasugrel in Patients With Chronic Coronary Disease Who Underwent Atherectomy.氯吡格雷与替格瑞洛和普拉格雷在接受血管成形术的慢性冠状动脉疾病患者中的真实世界比较。
Am J Cardiol. 2024 Apr 15;217:1-4. doi: 10.1016/j.amjcard.2024.02.006. Epub 2024 Feb 23.
2
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.替格瑞洛或普拉格雷与氯吡格雷用于慢性冠脉综合征经皮冠状动脉介入治疗的患者。
EuroIntervention. 2023 Mar 20;18(15):1244-1253. doi: 10.4244/EIJ-D-22-00654.
3
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.2009 - 2016年普拉格雷和替格瑞洛在经皮冠状动脉介入治疗后稳定性缺血性心脏病中的应用
Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.
4
Meta-Analysis Comparing Ticagrelor or Prasugrel Versus Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention.比较替格瑞洛或普拉格雷与氯吡格雷用于择期经皮冠状动脉介入治疗患者的荟萃分析
Am J Cardiol. 2021 Mar 15;143:160-162. doi: 10.1016/j.amjcard.2020.12.054. Epub 2020 Dec 28.
5
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y inhibitors in a large observational study.一项大型观察性研究比较了经皮冠状动脉介入治疗的急性冠状动脉综合征患者使用不同 P2Y 抑制剂的处方率和临床结局。
Int J Cardiol. 2019 Jan 1;274:21-26. doi: 10.1016/j.ijcard.2018.09.011. Epub 2018 Sep 5.
6
Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.急性冠状动脉综合征伴不良临床结局患者经皮冠状动脉介入治疗中静脉桥病变的抗血小板药物选择：来自英国心血管介入学会数据库的分析。
Catheter Cardiovasc Interv. 2018 Oct 1;92(4):659-665. doi: 10.1002/ccd.27493. Epub 2018 Jan 22.
7
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.澳大利亚人群中急性冠脉综合征的 P2Y12 抑制剂比较。
Heart Lung Circ. 2022 Aug;31(8):1085-1092. doi: 10.1016/j.hlc.2022.03.007. Epub 2022 May 17.
8
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.急性冠状动脉综合征患者经皮冠状动脉介入治疗中的当代抗血小板治疗：来自希腊抗血小板（GRAPE）注册研究的 1 年结果。
J Thromb Haemost. 2016 Jun;14(6):1146-54. doi: 10.1111/jth.13316. Epub 2016 May 4.
9
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.替格瑞洛或普拉格雷与氯吡格雷三联抗血小板治疗联合糖蛋白 IIb/IIIa 抑制剂用于接受 PCI 的 STEMI 患者：一项荟萃分析。
BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6.
10
Prasugrel in the treatment of acute coronary syndrome.普拉格雷治疗急性冠脉综合征。
Future Cardiol. 2020 Nov;16(6):559-568. doi: 10.2217/fca-2020-0018. Epub 2020 May 11.
Zotero 插件